Harvard researchers unveil FIND platform using DNA nanoswitches for drug screening

Harvard Researchers Unveil FIND Platform for High-Throughput Drug Screening

Key Clinical Takeaways:
• The FIND platform encodes individual experiments onto single DNA molecules, allowing massive parallel screening within one tube.
• The technique successfully identified compounds targeting PPAR-gamma and a coronavirus spike protein in initial tests.
• Findings remain restricted to test tube and cell culture experiments, requiring further validation before clinical application.

Limitations of Traditional High-Throughput Assays

Proteins rely on mutual interactions to function, and disruptions in these pathways often drive disease pathogenesis. Pharmaceutical agents frequently target these interfaces, as demonstrated by the diabetes drug Ozempic, which mimics the natural GLP-1 hormone to activate cellular receptors, and inhaled albuterol, which relaxes airway muscles by stimulating beta-2 adrenergic receptors.

Conventional drug discovery relies on multi-well plates to test compounds individually. Even advanced encoded library technologies generally identify only whether a single molecule binds to a target. These standard assays reveal whether a molecular key fits into a lock, but they fail to determine whether the lock actually turns.

DNA Nanoswitches as Programmable Scoreboards

To overcome these screening limitations, the research team created the Functional Interaction-based Nanoswitch Discovery (FIND) platform. Published on November 5, 2026, in the journal Science (10.1126/science.adt7185), the study details how the system utilizes long strands of DNA with potential binding proteins attached to each end. In their unbound state, the DNA strands remain linear. When the proteins bind successfully, the strands pull into a ring structure.

Compounds that promote protein interactions increase the proportion of ring-shaped DNA formations. The research team uses gel electrophoresis to separate the linear and circular shapes, as the ring configurations migrate more slowly through the gel. Every candidate molecule carries an associated nucleic acid barcode, allowing high-throughput sequencing to identify successful compounds.

“Our idea was to build each experiment on a single DNA molecule, so many experiments could happen in parallel in the same tube,” said Wesley Wong, senior author of the study and co-leader of the molecular robotics initiative at the Wyss Institute.

Mark Lipstein, co-first author of the research, noted that every candidate molecule remains physically linked to its individual experimental outcome. The test tube functions simultaneously as a laboratory vessel and a ledger.

Targeting PPAR-gamma and Viral Interactions in Early Testing

The investigators tested the platform using a DNA-encoded library containing 400 million members. Focusing on the metabolic target PPAR-gamma, they successfully screened for compounds that promote its interaction with a fragment of the coactivator protein CBP. These identified compounds increased lipid accumulation in cultured cells, confirming the expected activation profile of PPAR-gamma.

The team also isolated a nanobody capable of modulating the interaction between the SARS-CoV-2 spike protein and human cellular receptors, while validating the screening workflow using a known beta-2 receptor agonist.

Clinton Hansen, co-first author of the study, emphasized that these experimental outcomes currently remain restricted to in vitro test tubes and cell cultures. The identified molecules represent potential starting points for drug development and fundamental disease research rather than immediate clinical interventions.

The core technology originates from single-molecule measurement research conducted at the Wyss Institute, which shifted toward drug development following the adoption of gel analysis methods in 2015. The platform technology has since been licensed to a newly established startup company founded by members of the research team.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.